Published in Bone Marrow Res on May 28, 2012
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood (2009) 3.84
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood (2011) 2.58
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol (2005) 2.35
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood (2006) 2.18
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant (2001) 1.81
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol (2010) 1.76
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica (2010) 1.73
Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy (2009) 1.73
Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. Bone Marrow Transplant (2008) 1.72
Proteasome inhibitors in the treatment of multiple myeloma. Leukemia (2009) 1.68
Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol (2011) 1.60
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol (2011) 1.59
Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant (2009) 1.53
Uncontrolled-rate freezing and storage at -80 degrees C, with only 3.5-percent DMSO in cryoprotective solution for 109 autologous peripheral blood progenitor cell transplantations. Transfusion (2001) 1.51
A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant (2009) 1.43
Non-cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience. Clin Transplant (2011) 1.37
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc (2010) 1.34
Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood (2002) 1.32
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer (2005) 1.32
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia (2009) 1.30
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant (2008) 1.30
Treatment of newly diagnosed myeloma. Leukemia (2008) 1.27
Cryopreservation of hematopoietic stem cells. Am J Hematol (2007) 1.20
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant (2009) 1.18
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant (2010) 1.16
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant (2006) 1.14
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc (2008) 1.13
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica (2008) 1.06
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
Cryopreservation of hematopoietic and non-hematopoietic stem cells. Transfus Apher Sci (2006) 1.01
Gastrointestinal pathology of autologous graft-versus-host disease following hematopoietic stem cell transplantation: a clinicopathological study of 17 cases. Mod Pathol (2010) 1.00
Cryopreserving human peripheral blood progenitor cells. Curr Stem Cell Res Ther (2006) 0.99
Successful liquid storage of peripheral blood stem cells at subzero non-freezing temperature. Bone Marrow Transplant (2002) 0.97
Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist (2007) 0.97
High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood (1998) 0.93
Long-term hematological reconstitution and clinical evaluation of autologous peripheral blood stem cell transplantation after cryopreservation of cells with 5% and 10% dimethylsulfoxide at -80 degrees C in a mechanical freezer. Haematologica (2007) 0.92
Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature. Bone Marrow Transplant (2007) 0.92
Current status of autologous hematopoietic stem cell transplantation in myeloma. Bone Marrow Transplant (2008) 0.91
Ultra high-risk myeloma. Hematology Am Soc Hematol Educ Program (2010) 0.87
Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant (2009) 0.87
Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant (2008) 0.86
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica (2004) 0.86
Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant (2002) 0.85
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant (2010) 0.84
Stem cell transplantation for multiple myeloma: current and future status. Hematology Am Soc Hematol Educ Program (2011) 0.84
Eruption of lymphocyte recovery or autologous graft-versus-host disease? Int J Dermatol (2008) 0.84
Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (2006) 0.84
Optimization of peripheral blood stem cell mobilization. Stem Cells (1996) 0.83
Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant (2005) 0.83
Stem cell transplantation for multiple myeloma. Cancer Control (2004) 0.81
Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation. Bone Marrow Transplant (2006) 0.81
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag (2009) 0.81
CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome. Bone Marrow Transplant (2000) 0.81
Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed entirely on an outpatient basis. Am J Hematol (1998) 0.80
Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. Bone Marrow Transplant (2005) 0.80
The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplant (2006) 0.79
Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant (2007) 0.79
Evaluation of hematological reconstitution potential of autologous peripheral blood progenitor cells cryopreserved by a simple controlled-rate freezing method. Tohoku J Exp Med (2005) 0.79
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica (2008) 0.79
Genetic markers used for risk stratification in multiple myeloma. Genet Res Int (2011) 0.79
A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant (2003) 0.78
Hematopoietic cell transplantation using plasma and DMSO without HES, with non-programmed freezing by immersion in a methanol bath: results in 213 cases. Bone Marrow Transplant (1998) 0.78
Uncontrolled-rate freezing of peripheral blood progenitor cells allows successful engraftment by sparing primitive and committed hematopoietic progenitors. Haematologica (2003) 0.77
Storage of noncryopreserved periphered blood stem cells for transplantation. Ann Hematol (1996) 0.77
Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: long-term results. Arch Med Res (2000) 0.76
Overnight refrigerator storage of autologous peripheral progenitor stem cells without cryopreservation. Transfus Apher Sci (2007) 0.76
Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Ann Oncol (2007) 0.76
Non-cryopreserved, limited number (1 or 2) peripheral blood progenitor cell (PBPC) collections following GCSF administration provide adequate hematologic support for high dose chemotherapy. Hematol Oncol (1994) 0.76
Autologous graft-versus-host disease in a porcine bone marrow transplant model. Transplantation (2002) 0.76
Retrospective analysis of the results of high-dose chemotherapy with the support of autologous blood stem cells in patients with multiple myeloma. The experience of a single centre. Prague Med Rep (2010) 0.75